SoC (Coartem)

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

RecruitingNCT05750628

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2024-01-23End: 2026-06-23Target: 327Updated: 2025-07-30

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

CompletedNCT07235033

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2024-01-23End: 2025-03-19Updated: 2026-05-07

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)

CompletedNCT07811882

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2025-10-10End: 2026-07-01Updated: 2026-09-10

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)

RecruitingNCT07811908

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2026-02-12End: 2027-02-18Target: 120Updated: 2026-09-10